The latest biotech news

News and Trends 16 Aug 2022

Genentech lymphoma treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA […]

August 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Remedium raises more funds for osteoarthritis gene therapy candidate

Remedium Bio, Inc., a biotech company developing novel gene therapies, has closed more than $2.3 million in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss. The study is being undertaken in a collaboration with Tufts University […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Opthea secures up to $170M in financing for wet AMD treatment

Opthea Limited, a clinical-stage biopharma company developing novel therapies to treat highly prevalent and progressive retinal diseases, has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related […]

August 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Approval for Small Pharma major depressive disorder clinical trial

Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Scientists develop gel from spider silk proteins for biomedical applications

Researchers at Karolinska Institutet in Sweden and the Swedish University of Agricultural Sciences have discovered spider silk proteins can be fused to biologically active proteins and be converted into a gel at body temperature. One of the goals is to develop an injectable protein solution that forms a gel inside the body, which could be […]

August 15, 2022 - 3 minutesmins - By Jim Cornall

Short Wave Pharma to start anorexia clinical trials

News and Trends 15 Aug 2022

Short Wave Pharma to start clinical trial for anorexia nervosa treatment

Short Wave Pharma Inc., a biopharma company developing patent pending psychedelic compositions and methods of delivery, has signed a clinical trial agreement with the Sheba Fund for Health Services and Research and with Eitan Gur, principal investigator and head of the Sheba Medical Center Department for Eating Disorders, and Yoel Golbert, co–investigator at the center. […]

August 15, 2022 - 3 minutesmins - By Jim Cornall

Roche announces Xofluza approval and new Elecsys IGRA SARS-CoV-2 test

News and Trends 15 Aug 2022

Roche announces influenza drug approval and new COVID test

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

August 15, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Aptinyx fibromyalgia drug misses endpoint

Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s primary endpoint. “We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up phase […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

Tetra Bio-Pharma Inc., a company working in cannabinoid-based drug discovery and development, has announced it has entered into a subscription agreement with investment vehicle Global Corporate Finance Opportunities 16 (GCFO 16). The announcement came yesterday (August 11) after Alpha Blue Ocean (ABO) advised the partnership whereby Canadian-based Tetra agrees to issue investor GCFO 16 senior […]

August 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 12 Aug 2022

argenx secures European Commission approval for generalized myasthenia gravis treatment

Dutch immunology company argenx says the European Commission (EC) has granted marketing authorization for VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The approval is applicable to all 27 European Union (EU) Member States plus Iceland, […]

August 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

On this week’s podcast, we have conversations with ARCH Venture Partners’ managing director Kristina Burow; founder and CEO of Micropep Thomas Laurent; Kylie O’Keefe, SVP, commercial & corporate strategy at PTC Therapeutics, and Juan Carlos Jaramillo, chief medical officer of Valneva. ARCH Venture Partners closes $2.97B biotech fund ARCH Venture Partners has announced the closing […]

August 12, 2022

conveyor belt of medical vials for scale up production

News and Trends 11 Aug 2022

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional U.S. patent application covering the company’s novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.” CAR-T cells are effective at treating certain lymphomas and leukemias with […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Genentech lymphoma treatment gets FDA approval

Remedium raises more funds for osteoarthritis gene therapy candidate

Opthea secures up to $170M in financing for wet AMD treatment

Approval for Small Pharma major depressive disorder clinical trial

Scientists develop gel from spider silk proteins for biomedical applications

Short Wave Pharma to start clinical trial for anorexia nervosa treatment

Roche announces influenza drug approval and new COVID test

Aptinyx fibromyalgia drug misses endpoint

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

argenx secures European Commission approval for generalized myasthenia gravis treatment

Beyond Biotech podcast 9: ARCH Venture Partners, Micropep, PTC Therapeutics, Valneva

Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!